Sanofi and Baurs partner to leverage synergies in Sri Lanka

A. Baur & Co. MD/CEO Rolf Blaser (left) with Sanofi Lanka Country Manager Mario Alphael 

Sanofi India Ltd. (SIL), Sanofi-Aventis Singapore Ltd and A. Baur & Co. Ltd. have come together to form a partnership for distribution and marketing of Sanofi products in Sri Lanka. 

Going forward, Baurs, a known name to us all, will bring onboard their legacy and expertise to manage the import, distribution and marketing for Sanofi products in Sri Lanka. 

Baurs’ reputation of being a highly ethical and professional organisation has helped it build its wide distribution network and strong credibility amongst all stakeholders. The parties are happy to confirm the commitment towards Sri Lanka and to ensure the availability of efficacious, safe and good quality medicines to the patients of Sri Lanka. 

For over five decades, Sanofi Lanka Ltd. has transformed scientific innovation into healthcare solutions and helped prevent diseases, achieve wellness and treat a vast range of illnesses. 

Since 1945, Baurs has built its healthcare competency through trust, reliability, quality and innovation. With its impressive distribution network and impactful marketing competencies, Baurs has become the most preferred distributor to represent the world’s largest and renowned pharmaceutical companies, in Sri Lanka.

“We are very happy to confirm Sanofi’s dedication towards our country through Baurs, to ensure uninterrupted supply of world-class medicines to patients in Sri Lanka,” commented Baurs Healthcare Director Nishantha Weerasinghe.

This partnership will ensure that doctors continue to have access to information on science, medicine, R&D and innovation in Sanofi’s portfolio, while patients can remain reassured of high-quality, end-to-end supply and distribution. 

Sanofi India Managing Director Rajaram Narayanan said: “The strong operational efficiencies and legacy that Baurs has built for itself in this market will further Sanofi’s commitment in Sri Lanka to focus on R&D, innovation and science. We are confident this association will enable better reach for Sanofi’s global brands and foster an agile operating model that is adapted to local market needs.”

“It is very interesting to learn that Sanofi records its beginning in 1885 with the first vaccine against rabies, just one year after Alfred Baur arrived in Sri Lanka in 1884. Given our companies are very likeminded and our value systems are practically identical, striving towards contribution to society in a highly ethical & moral manner, while cherishing quality and innovation, we consider this as the beginning of a very long lasting mutually beneficial partnership,” said Baurs Managing Director/CEO Rolf Blaser.